Gila Therapeutics, Inc.
Therapeutics targeting the tongue-brain neural pathway for obesity and cardiometabolic disease treatment
- Sector
- Biotech
- Headquarters
- Edina, MN
- Founded
- 2014
- Latest Form D
- $400K, Dec 2023
- Total capital
- $4.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $4.1M
- 6 Form D · last Dec 2023
- 35 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 22 pending · first 2024
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$400K
- Private capital raisedForm D · SEC · 5th filing$356K
- Private capital raisedForm D · SEC · 4th filing$402K
- Private capital raisedForm D · SEC · 3rd filing$314K
- Offering registeredForm D · SEC · 2nd filing$500K
- Private capital raisedForm D · SEC · 1st filing$2.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing in Biotech · 4373 companies
Line = median- Federal contractsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Andres J. AcostaResearcherPromoterLinked by 1 patent
- Christopher R. DeSouzaDirectorNamed in SEC Form D filings
- Christopher de SouzaDirectorNamed in SEC Form D filings
- Jon FreemanExecutive OfficerNamed in SEC Form D filings
- Michael R. CardenasPromoterNamed in SEC Form D filings
- Praveen TyleDirectorNamed in SEC Form D filings
Show all 13 people
- Richard HoranDirectorNamed in SEC Form D filings
- Sangeeta KashyapExecutive OfficerNamed in SEC Form D filings
- Scott SchorerExecutive Officer, DirectorNamed in SEC Form D filings
- Sergei J. ZolutukhinPromoterNamed in SEC Form D filings
- Thomas J. VasicekExecutive Officer, DirectorNamed in SEC Form D filings
- Timothy BarberichDirectorNamed in SEC Form D filings
- Tom VasicekExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 23- PendingCompositions And Methods For Treating Metabolic DiseasesUSPTOApplication 19066477
- PendingPeptide Yy Pharmaceutical Formulations, Compositions, And MethodsUSPTOApplication 18999019
- PendingCompositions And Methods For Activating A Neural ReceptorUSPTOApplication 18577369
Show all 23 patent records
- Compositions And Methods For Treating Metabolic DiseasesJul 31, 2025 · Application 19066477Pending
- Peptide Yy Pharmaceutical Formulations, Compositions, And MethodsApr 17, 2025 · Application 18999019Pending
- Compositions And Methods For Activating A Neural ReceptorOct 17, 2024 · Application 18577369Pending
- Methods And Kits For Inducing Satiety And Treating Metabolic DisordersAug 29, 2024 · Application 18572395Pending
- Peptide Yy Pharmaceutical Formulations, Compositions, And MethodsFeb 27, 2024 · US 11,911,445Granted
- Compositions And Methods For Treating Metabolic DiseasesMar 16, 2023 · Application 17730960Pending
- Peptide Yy Pharmaceutical Formulations, Compositions, And MethodsMay 12, 2022 · Application 17335610Pending
- Peptide Yy Pharmaceutical Formulations, Compositions, And MethodsOct 7, 2021 · Application 17335753Pending
- Compositions and Methods for Treating Metabolic DiseasesJul 25, 2019 · Application 16243170Pending
- Peptide Yy Pharmaceutical Formulations, Compositions, And MethodsApplication PCTUS2019014720Pending
- Compositions And Methods For Treating Metabolic DiseasesApplication PCTUS2019012820Pending
- Peptide YY Pharmaceutical Formulations, Compositions and MethodsApplication 62669191Pending
- Peptide YY Pharmaceutical Formulations and MethodsApplication 62620580Pending
- Compositions And Methods For Treating Metabolic Diseases With Topical-lingual Receptor AgonistsApplication PCTUS2025022140Pending
- Compositions And Methods For Treating Metabolic DiseasesApplication 62615262Pending
- Compositions And Methods For Treating Metabolic Diseases With Topical-lingual Receptor AgonistsApplication 63571114Pending
- Methods For Inducing Satiety And Treating Metabolic DisordersApplication 18577326Pending
- Compositions And Methods For Activating A Neural ReceptorApplication PCTUS2022036437Pending
- Methods For Inducing Satiety And Treating Metabolic DisordersApplication PCTUS2022036439Pending
- Methods And Kits For Inducing Satiety And Treating Metabolic DisordersApplication PCTUS2022034836Pending
- Methods For Inducing Satiety And Treating Metabolic DisordersApplication 63219407Pending
- Compositions And Methods For Activating A Neural ReceptorApplication 63219409Pending
- Methods And Kits For Inducing Satiety And Treating Metabolic DisordersApplication 63214382Pending
Related companies, and why
- Black Bear Energy, Inc.Similar federal contract value in Biotech · null in contracts
- SignPath Pharma, Inc.Similar federal contract value in Biotech · null in contracts
- OverT Bio, Inc.Similar federal contract value in Biotech · null in contracts
- SANARENTERO LLCSimilar federal contract value in Biotech · null in contracts
- KARYOPHARM THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- Umoja BiopharmaSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .